Participated · Series B · Jan 2026

Tenpoint Therapeutics, Ltd. is a global commercial biotech company focused on rejuvenating vision in the aging eye. Its lead product, YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution 2.75% / 0.1%), is the first and only dual-agent eye drop approved for presbyopia, a condition that affects about 128 million people in the United States and roughly 2 billion worldwide. The company plans to launch YUVEZZI in early Q2, supported by a leadership team with extensive ophthalmology experience. Tenpoint emphasizes real-world needs by partnering closely with eye-care professionals to bring innovative treatments to market. Financially, the firm recently bolstered its balance sheet with $85 million in Series B equity financing and a $150 million non-dilutive term loan facility, bringing in both new and existing blue-chip investors. This capital positions Tenpoint to execute a large-scale commercial rollout while continuing to build its pipeline of therapies for the aging eye.

Participated · Series B · Sep 2025

ARTHEx Biotech is a clinical-stage company specializing in targeted RNA medicines that precisely modulate gene expression across skeletal muscle, heart and brain tissues. Its lead program, ATX-01, is an oleic-acid-conjugated anti-miR oligonucleotide designed to inhibit microRNA-23b and restore MBNL protein function in myotonic dystrophy type 1 (DM1); the drug is currently being evaluated in the randomized, placebo-controlled Phase I/IIa ArthemiR™ study. ATX-01 has secured Orphan Drug Designation in both the United States and Europe, as well as Rare Pediatric Disease Designation from the FDA. Preclinical data show the therapy increases MBNL production, reduces toxic DMPK mRNA and corrects spliceopathy in animal and cell models. Beyond DM1, ARTHEx is using its delivery platform to build a pipeline for additional muscular, CNS, cardiac and pulmonary diseases with high unmet need. The company’s headquarters are in Valencia, Spain, and it recently upsized its Series B financing to support preparation for a registrational study of ATX-01 and to broaden its pipeline. Including this round, the company has attracted backing from a consortium of European and U.S. life-science investors.

Participated · Series A · Sep 2025

Integra Therapeutics is a spin‑out from Pompeu Fabra University (founded in 2020) developing the FiCAT platform, which combines CRISPR‑Cas accuracy with an engineered piggyBac transposase to address payload size, stability, and accuracy limitations in gene therapy. The platform targets applications across genetic, oncological, and autoimmune diseases and is being used to advance next‑generation CAR‑T therapies. The company is also developing a first gene therapy candidate for a rare pediatric liver disease, supported by an EIC Accelerator grant. Integra plans to integrate new advances into FiCAT, expand cell engineering capabilities, and facilitate technology transfer to the pharmaceutical industry. The team intends to use new funding to support preclinical validation of CAR‑T programs and to scale its cell engineering operations. Leadership includes co‑founders Dr. Marc Güell and Dr. Avencia Sánchez‑Mejías; the company is based in Barcelona. Integra Therapeutics is a Barcelona‑based biotech spin‑off (founded 2020 from Pompeu Fabra University) developing FiCAT, a gene‑writing platform intended to overcome current limits on size, precision and stability. Its core product, FiCAT, targets ex vivo engineering of T cells and hematopoietic stem cells and systemic in vivo gene therapy using non‑viral lipid nanoparticle (LNP) delivery. The company plans to use initial funding to support pre‑marketing activities for cell therapy applications across rare diseases, autoimmune disorders and oncology. In parallel, Integra will generate proof‑of‑concept data for a first gene therapy aimed at a serious pediatric hepatic disease using systemic non‑viral delivery. Longer term, Integra intends to expand FiCAT to extra‑hepatic indications and to pursue licensing and co‑development partnerships to broaden patient access. The company is led by co‑founders Dr Marc Güell and Dr Avencia Sánchez‑Mejías. Integra Therapeutics develops next-generation gene writing tools and is advancing a gene writing platform called FiCAT to improve safety and efficacy of advanced therapies. The company targets prevention and treatment of genetic diseases and cancers with unmet medical needs. Co-founded by Marc Güell and Avencia Sánchez-Mejías, Integra is working toward a FiCAT platform prototype and preclinical validation. The planned preclinical work includes in vivo and ex vivo models. Financially, the company raised an additional €1.5m in seed funding in March 2022 following a €4.5m seed raise in December. The new investment includes participation from Columbus Venture Partners, which will place a representative on the board. Integra Therapeutics (Integra Tx) is a biotechnology spin-off from Pompeu Fabra University focused on creating next-generation gene writing tools to make advanced therapies safer and more effective. The company was founded in late 2020 based on technology developed in the Translational Synthetic Biology Lab led by Dr. Marc Güell and Avencia Sánchez-Mejías. Integra intends to complete a prototype of its gene writing platform and carry out preclinical validation using in vivo and ex vivo models. It plans to manage and expand its patent portfolio through 2022 and 2023. The company raised €4.5M in its first round of funding to support these development activities. After prototyping and preclinical work, Integra plans to open a Series A to seek regulatory approval and carry out clinical trials with patients.

Participated · Series A · Mar 2025

Augustine Therapeutics develops selective inhibitors of the cytosolic histone deacetylase 6 (HDAC6) enzyme for chronic indications. Its lead program, AGT-100216, is described as the first selective HDAC6 inhibitor designed for long-term treatment of Charcot-Marie-Tooth (CMT) disease. The company highlights a non-hydroxamate, non-hydrazide chemotype intended to provide selectivity and avoid limitations of other chemotypes, and says the approach is built for chronic diseases. Augustine plans to use newly raised capital to advance AGT-100216 through a Phase I/II proof-of-concept clinical trial in CMT. The company targets neuromuscular, neurodegenerative and cardio-metabolic diseases with this selective HDAC6 approach. Augustine is led by CEO Gerhard Koenig and was founded on research by Prof. Ludo Van Den Bosch at VIB-KU Leuven in Belgium. The recent financing strengthens its balance sheet to support clinical development. Augustine Therapeutics is developing novel, potent, subtype-selective small-molecule inhibitors of the cytosolic HDAC6 enzyme targeting neurodegenerative and cardiometabolic diseases. Its lead candidate, AGT100216, is a peripherally restricted selective HDAC6 inhibitor that has shown impressive preclinical efficacy in Charcot‑Marie‑Tooth (CMT) studies and peripheral neuropathies induced by chemotherapy (CIPN). The company’s chemistry is distinct from first-generation hydroxamate-based HDAC6 inhibitors and is designed to safely and selectively reverse pathophysiological changes associated with neuromuscular and neurodegenerative diseases. Augustine plans to advance AGT100216 into a Phase 1/2 first-in-human clinical trial in 2025 and to develop next-generation candidates with peripheral-restricted or brain-penetrant properties. Proceeds from the financing will also support expansion of the executive and R&D teams. Augustine was founded in 2019 as a VIB-KU Leuven spin-off and is based in Leuven, Belgium. Augustine Therapeutics is focused on the discovery and development of innovative therapeutics for Charcot‑Marie‑Tooth disease (CMT) and other neuromuscular disorders. The company is rooted in research from the VIB–KU Leuven labs of Ludo Van Den Bosch and collaborations between the labs of Joris de Wit and Bart De Strooper, which uncovered biological pathways and therapeutic targets in peripheral neuropathies. VIB Discovery Sciences is leading the preclinical development of Augustine’s new therapeutics and will apply industry-trained drug discovery expertise to the early pipeline. Augustine completed a €4.2 million seed financing to support target validation and early-stage development. Day-to-day interim management is being handled by Ward Capoen (V-Bio Ventures) and Jérôme Van Biervliet (VIB) while the company seeks a dedicated management team. The company aims to advance validated targets toward novel treatments that address the limited therapeutic options for CMT patients.

Led · Seed · Jul 2023

Orikine Bio focuses on discovering, researching, and developing precision-engineered bi-specific cytokine drugs for autoimmune and inflammatory disorders. Its proprietary FoldikineTM platform re-designs natural cytokines into optimized, dual-acting proteins called Foldikines that can more precisely modulate immune responses. The lead candidate, FoldikineTM ORK-1, targets autoimmune and inflammatory diseases and is currently in preclinical development. Orikine plans to use fresh capital to establish preclinical proof-of-concept data for ORK-1, a key step toward future clinical trials. Beyond ORK-1, the company intends to expand its pipeline to address additional autoimmune, inflammatory, and oncology indications. No revenue or user metrics have been disclosed, reflecting the company’s early R&D stage. Financially, Orikine Bio relies on innovation grants and research funding to progress its platform and pipeline.